

DIASORIN

Sector: Consumers

NEUTRAL

Price: Eu67.76 - Target: Eu74.00

More De-Risked Baseline, But No Re-rating Catalyst in Sight

Giorgio Tavolini +39-02-77115.279

giorgio.tavolini@intermonte.it

Stock Rating

Rating: Unchanged


Target Price (Eu): Unchanged

	2026E	2027E	2028E
Chg in Adj EPS	0.0%	-1.2%	-1.3%

Next Event

1H26 results out 31 July

DIASORIN - 12M Performance



Stock Data

Reuters code: DIAS.MI

Bloomberg code: DIA IM

Performance	1M	3M	12M
Absolute	7.5%	-3.5%	-27.6%
Relative	5.3%	-8.8%	-48.2%
12M (H/L)		95.10/55.62	
3M Average Volume (th):		373.24	

Shareholder Data

No. of Ord shares (mn): 56

Total no. of shares (mn): 56

Mkt Cap Ord (Eu mn): 3,788

Total Mkt Cap (Eu mn): 3,788

Mkt Float - Ord (Eu mn): 1,602

Mkt Float (in %): 42.3%

Main Shareholder:

FINDE SS (G. Denegri) 45.0%

Balance Sheet Data

Book Value (Eu mn): 1,445

BVPS (Eu): 19.39

P/BV: 3.5

Net Financial Position (Eu mn): -673

Enterprise Value (Eu mn): 4,465

Overall, the DiaSorin Investor Day held no major surprises: the BP confirmed existing market expectations rather than raising the bar, with management describing the targets as ambitious but achievable. The BP trajectory reflects a more de-risked baseline vs. the previous plan, incorporating slower ImmunoDX growth (mid-single-digit from ~8% previously, reflecting China headwinds, normalising EU testing volumes, incoming pricing competition on latent TB); a more gradual LIAISON PLEX ramp up (>€180m by FY30 from €200m by FY27); and a lower 2030 adj. EBITDA margin target (34-35% by 2030 from 36-37% by FY27) to reflect China VBP, tariffs, NIH/life science funding cuts, and NES investment costs. There was some disappointment on capital allocation, with no buyback programme quantified in the absence of near-term M&A opportunities. On the positive side, the pipeline is well-defined, with 20+ new specialty IVD assays to be launched by 2030 across autoimmunity, GI, and infectious diseases. We are fine-tuning estimates, confirming our TP of €74 and NEUTRAL rating. The stock is currently trading in line with peers at 16x P/E'27- leaving limited room for disappointment.

■ **Financials in line.** 2026 guidance was confirmed (revenue +5-6% @CER, adj. EBITDA margin 32-33%), while the +6-8% 2026-30 revenue CAGR and the 2030 adj. EBITDA margin target of 34-35% - implying ~200bp of expansion vs. 2026 - are broadly in line with our estimates and consensus. Revenue mix: MolecularDX is expected to grow from 17% to 30% of total revenues by 2030, with ImmunoDX dropping from 70% to 60% and LTG from 13% to 10%. Geographically, North America will move from 52% to 60% of revenues, driven by the NES US ramp-up, with moderate compression of both Europe and RoW. On FCF, the ~€1bn cumulative 2027-2030 target was essentially in line with estimates (our exp. €1.1bn, cons. €0.9bn). Looking at capital allocation, the plan formalised four FY27-30 priorities: organic investment (~35% of OpFCF), dividends (~20%), selective bolt-on M&A, and as-yet unquantified opportunistic buybacks. Continued de-leverage is flagged as a parallel objective.

■ **Operational highlights.** On ImmunoDX, 20+ new assays across autoimmunity, hypertension, GI, and infectious diseases, alongside a new LIAISON XL platform (launch in 1H27) targeting lab consolidation trends with enhanced throughput and TLA integration, and complementary diagnostics for precision medicine including one Companion Diagnostic product. The US hospital strategy targets ~900 by 2030 (~40% of US hospitals) from ~600 hospitals currently served. On MeMed, the target is >250 US hospital customers by 2030, with adoption supported by Jupiter study data and the pending CMS unbundling request. On MolecularDX, the key growth drivers are the LIAISON NES for near-patient/POC testing targeting >\$150m in the US market by 2030, the LIAISON PLEX multiplex platform, targeting >€180m globally by 2030 (old target: €200mn by 2027), and continued specialty low-plex expansion on MDX/MDX Plus. On LTG, the focus remains on deepening pharma and academic partnerships and expanding into drug discovery and vaccine development.

Key Figures & Ratios	2024A	2025A	2026E	2027E	2028E
Sales (Eu mn)	1,185	1,195	1,241	1,312	1,393
EBITDA Adj (Eu mn)	393	394	401	431	468
Net Profit Adj (Eu mn)	236	223	220	238	264
EPS New Adj (Eu)	4.217	3.986	3.932	4.256	4.722
EPS Old Adj (Eu)	4.217	3.986	3.932	4.309	4.785
DPS (Eu)	1.200	1.300	1.350	1.400	1.450
EV/EBITDA Adj	15.5	13.8	11.1	10.0	8.8
EV/EBIT Adj	20.1	17.9	14.4	12.7	11.2
P/E Adj	16.1	17.0	17.2	15.9	14.3
Div. Yield	1.8%	1.9%	2.0%	2.1%	2.1%
Net Debt/EBITDA Adj	1.6	1.5	1.7	1.2	0.7

IMPORTANT DISCLOSURES

The reproduction of the information, recommendations and research produced by Intermonte SIM contained herein and of any its parts is strictly prohibited. None of the contents of this document may be shared with third parties without authorisation from Intermonte.

This report is directed exclusively at market professional and other institutional investors (institutions) and is not for distribution to person other than "Institution" ("Non-Institution"), who should not rely on this material. Moreover, any investment or service to which this report may relate will not be made available to Non-Institution.

The information and data in this report have been obtained from sources which we believe to be reliable, although the accuracy of these cannot be guaranteed by Intermonte. In the event that there be any doubt as to their reliability, this will be clearly indicated. The main purpose of the report is to offer up-to-date and accurate information in accordance with regulations in force covering "recommendations" and is not intended nor should it be construed as a solicitation to buy or sell securities.

This disclaimer is constantly updated on Intermonte's website www.intermonte.it under LEGAL NOTICES. Valuations and recommendations can be found in the text of the most recent research and/or reports on the companies in question. For a list of all recommendations made by Intermonte on any financial instrument or issuer in the last twelve months consult the web page CUSTOMER AREA.

Intermonte distributes research and engages in other approved activities with respect to Major U.S. Institutional Investors ("Majors") and other Qualified Institutional Buyers ("QIBs"), in the United States, via Plural Securities LLC under SEC 15a-6 guidelines. Intermonte is not registered as a broker dealer in the United States under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is not a member of the Securities Investor Protection Corporation ("SIPC"). Plural Securities LLC is registered as a broker-dealer under the Exchange Act and is a member of SIPC.

ANALYST CERTIFICATION

For each company mentioned in this report the respective research analyst hereby certifies that all of the views expressed in this research report accurately reflect the analyst's personal views about any or all of the subject issuer (s) or securities. The analyst (s) also certify that no part of their compensation was, is or will be directly or indirectly related to the specific recommendation or view in this report.

The analyst (s) responsible for preparing this research report receive(s) compensation that is based upon various factors, including Intermonte's total profits, a portion of which is generated by Intermonte's corporate finance activities, although this is minimal in comparison to that generated by brokerage activities. Intermonte's internal procedures and codes of conduct are aimed to ensure the impartiality of its financial analysts. The exchange of information between the Corporate Finance sector and the Research Department is prohibited, as is the exchange of information between the latter and the proprietary equity desk in order to prevent conflicts of interest when recommendations are made.

The analyst responsible for the report is not a) a resident of US; b) an associated person of a U.S. broker-dealer; c) supervised by a supervisory principal of a U.S. broker-dealer. This Research Report is distributed in the U.S. through Plural Securities LLC, 950 3rd Avenue, Suite 1702, NY 10022, USA.

GUIDE TO FUNDAMENTAL RESEARCH

The main methods used to evaluate financial instruments and set a target price for 12 months after the investment recommendation are as follows:

- Discounted cash flow (DCF) model or similar methods such as a dividend discount model (DDM)
- Comparison with market peers, using the most appropriate methods for the individual company analysed: among the main ratios used for industrial sectors are price/ earnings (P/E), EV/EBITDA, EV/EBIT, price /sales
- Return on capital and multiples of adjusted net book value are the main methods used for banking sector stocks, while for insurance sector stocks return on allocated capital and multiples on net book value and embedded portfolio value are used
- For the utilities sector comparisons are made between expected returns and the return on the regulatory asset base (RAB)

Some of the parameters used in evaluations, such as the risk-free rate and risk premium, are the same for all companies covered, and are updated to reflect market conditions. Currently a risk-free rate of 4.0% and a risk premium between 5.5% - 6.0% are being used.

Frequency of research: quarterly.

Reports on all companies listed on the FTSEMIB40 Index, most of those on the MIDEX Index and the main small caps (regular coverage) are published at least once per quarter to comment on results and important newsflow.

A draft copy of each report may be sent to the subject company for its information (without target price and/or recommendations), but unless expressly stated in the text of the report, no changes are made before it is published.

Explanation of our ratings system:

BUY: stock expected to outperform the market by over 25% over a 12 month period;

OUTPERFORM: stock expected to outperform the market by between 10% and 25% over a 12 month period;

NEUTRAL: stock performance expected at between +10% and -10% compared to the market over a 12 month period;

UNDERPERFORM: stock expected to underperform the market by between -10% and -25% over a 12 month period;

SELL: stock expected to underperform the market by over 25% over a 12 month period.

Prices: The prices reported in the research refer to the price at the close of the previous day of trading

CURRENT INVESTMENT RESEARCH RATING DISTRIBUTIONS

Intermonte SIM is authorised by CONSOB to provide investment services and is listed at n° 246 in the register of brokerage firms.

As at 21 May 2026 Intermonte's Research Department covered 136 companies. Intermonte's distribution of stock ratings is as follows:

BUY:	32.35%
OUTPERFORM:	39.71%
NEUTRAL:	27.94%
UNDERPERFORM:	00.00%
SELL:	00.00%

The distribution of stock ratings for companies which have received corporate finance services from Intermonte in the last 12 months (80 in total) is as follows:

BUY:	53.75%
OUTPERFORM:	28.75%
NEUTRAL:	16.25%
UNDERPERFORM:	01.25%
SELL:	00.00%

CONFLICT OF INTEREST

In order to disclose its possible conflicts of interest Intermonte SIM states that:

Intermonte SIM S.p.A. operates or has operated in the last 12 months as the person in charge of carrying out the share buyback plan approved by the shareholders' meeting of AZIMUT, ECOSUNTEK, ELEN., ELICA, FILA, INTERCOS, INTRED, PHARMANUTRA, SESA, SG COMPANY, STAR7, SYS-DAT, TMP GROUP, UNIDATA, VALSOIA, WEBUILD

Intermonte SIM S.p.A. provides or has provided corporate brokerage services to ABC COMPANY, AEROPORTO GUGLIELMO MARCONI DI BOLOGNA, ALLCORE, ALMAWAVE, ANTARES VISION, AVIO, CASTA DIVA GROUP, CUBE LABS, CY4GATE, DOMINION HOSTING HOLDING, ELICA, ESPRINET, EVISIO, EXECUS, FINE FOODS & PHARMACEUTICALS NTM, FRANCHI UMBERTO MARMU, GPI, GREEN OLEO, HIGH QUALITY FOOD, IGD, IKONISYS SA, INTRED, ISCC FINTECH, LEMON SISTEMI, LUVÉ, MAPS, MARE ENGINEERING GROUP, NEODECORTECH, NOTORIOUS PICTURES, PREATONI GROUP, REDELI, REDFISH LONGTERM CAPITAL, REVO INSURANCE, REWAY GROUP, SERI INDUSTRIAL, SPINDOX, STAR7, TECNO, ULISSE BIOMED, WIIT, XENIA HOTELLERIE SOLUTION, Zest Group SpA in the last 12 months

Intermonte SIM S.p.A. operates or has operated in the last 12 months as Financial Content Provider on the company ALLCORE, ALMAWAVE, B&C SPEAKERS, BANCA SISTEMA, BIFIRE, CASTA DIVA GROUP, COFLE, COM.TEL, CUBE LABS, CY4GATE, DIGITOUCH, DOMINION HOSTING HOLDING, ECOSUNTEK, ELES, ELICA, ENERGY, EVISIO, EXECUS, FIERA MILANO, FILA, FOPE, G.M. LEATHER, GREEN OLEO, HIGH QUALITY FOOD, IGD, IKONISYS SA, INTERCOS, INTRED, ISCC FINTECH, LEMON SISTEMI, MAPS, MARE ENGINEERING GROUP, MASI AGRICOLA, MATECA FINTEC, MISITANO & STRACUZZI SPA, NEODECORTECH, NOTORIOUS PICTURES, OLIDATA, PREATONI GROUP, RACING FORCE, REDELI, REDFISH LONGTERM CAPITAL, SG COMPANY, SIMONE, SPINDOX, TAMBURI, TECNO, TMP GROUP, ULISSE BIOMED, XENIA HOTELLERIE SOLUTION, Zest Group SpA

Intermonte SIM S.p.A. performs or has performed in the last 12 months the role of intermediary appointed in the public purchase and/or exchange offer transaction of ANTARES VISION, MARE ENGINEERING GROUP, TINEXTA

Intermonte SIM S.p.A. operates or has operated in the last 12 months as liquidity provider of BANCA SISTEMA, Zest Group SpA

Intermonte SIM has acted as counterparty to WIIT Fin S.r.l. in connection with call and put options having WIIT S.p.A. shares and dividends as reference underlying.

Intermonte SIM is acting as financial advisor to Banca CF+ in the context of the public tender offer promoted on Banca Sistema.

Intermonte SIM is acting as financial advisor to TIM in relation to the company's saving shares conversion.

Intermonte SIM S.p.A. performs or has performed in the last 12 months the role of financial advisor for BANCA GENERALI, BANCO BPM, MARE ENGINEERING GROUP, TELECOM ITALIA, TINEXTA

Intermonte SIM S.p.A. operates or has operated in the last 12 months as market maker on financial instruments with underlying shares issued by AZA, AMPLIFON, AZIMUT, BANCA GENERALI, BANCA IFIS, BANCA MEDIOLANUM, BANCO BPM, BCA MPS, BCA POP SONDRIO, BFF BANK, Bper Banca, BREMBO, BUZZI, CAMPARI, DANIELI & C, DIASORIN, ENEL, ENI, ERG, FERRARI, FINCOBANK, INDUSTRIE DE NORA, INTERPUMP GROUP, INTESA SANPAOLO, INWIT, IREN, ITALGAS, IVECO GROUP, LEONARDO, LOTTOMATICA GROUP, MEDIOPANCA, MFE B, MONCLER, MONDADORI EDIT., NEXI, OVS, PIRELLI & C, POSTE ITALIANE, PRYSMIAN, SAPEM, SESA, SNAM S.p.A., STELLANTIS, STMICROELECTRONICS, TECHNOGYM, TECHNOPE, TELECOM ITALIA, TELECOM ITALIA R, TENARIS, TERNA, UNICREDIT, UNIPOL, WEBUILD

Intermonte Sim S.p.A. has or had in the last 12 months a marketing contract on instruments issued by BARCLAYS, BNP PARIBAS, GOLDMAN SACHS GROUP INC, LEONTEQ, MAREX FINANCIAL, MEDIOPANCA, MORGAN STANLEY, NATIXIS, SOCIETE GENERALE, UNICREDIT, VONTOBEL N

Intermonte SIM S.p.A. performs or has performed in the last 12 months the role of specialist on financial instruments issued by ABITARE IN, AQUAFIL, BANCA IFIS, BANCA SISTEMA, COFLE, COM.TEL, DIGITOUCH, ECOSUNTEK, ELEN., EMAK, ENERGY, FNM, GEFRAN, GREEN OLEO, INTRED, MATECA FINTEC, MISITANO & STRACUZZI SPA, MONDADORI EDIT., OLIDATA, OMER, PHARMANUTRA, POWERSOFT, QF ALPHA IMM, REPLY, SESA, SG COMPANY, SOMEK, STAR7, SYS-DAT, TAMBURI, TESMEC, THE ITALIAN SEA GROUP, TINEXTA, TMP GROUP, TXT E-SOLUTIONS, UNIDATA with the obligation to disseminate studies

Intermonte SIM S.p.A. plays or has played in the last 12 months the role of sponsor for UNIDATA S.p.A.

© Copyright 2026 by Intermonte SIM - All rights reserved

It is a violation of national and international copyright laws to reproduce all or part of this publication by email, xerography, facsimile or any other means. The Copyright laws impose heavy liability for such infringement. The Reports of Intermonte SIM are provided to its clients only. If you are not a client of Intermonte SIM and receive emailed, faxed or copied versions of the reports from a source other than Intermonte SIM you are violating the Copyright Laws. This document is not for attribution in any publication, and you should not disseminate, distribute or copy this e-mail without the explicit written consent of Intermonte SIM.

INTERMONTE will take legal action against anybody transmitting/publishing its Research products without its express authorization.

INTERMONTE Sim strongly believes its research product on Italian equities is a value added product and deserves to be adequately paid.

Intermonte Sim sales representatives can be contacted to discuss terms and conditions to be supplied the INTERMONTE research product.

INTERMONTE SIM is MIFID compliant - for our Best Execution Policy please check our Website <https://www.intermonte.it/avvertenze-legali/mifid-ii.html>

Further information is available.